PATENT CLAIM ANALYSIS

Application Number: 16211687
Application Type: Utility
Filing Date: 2018-12
Publication Date: 2019-04
Patent Classification: ["514", "469000"]

Abstract:
Embodiments of the invention relate to the treatment of sleep disturbances in individuals with Smith-Magenis Syndrome (SMS).

Claim (Index 14):
The method of  claim 12 , wherein the tasimelteon is administered at a dosage of between about 5 mg/day and about 100 mg/day.

Metadata:
- Claim Count in Document: 1.0
- Percentile: 98.0
- Lexical Diversity: 1.11111
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['15326934', '15378353', '15822162', '14374257', '16180316']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.6704704065117976
- 35 USC 102 Novelty (BERT): 0.5283183935033136
- Combined Prediction Score: 0.6562552052109492
- Mean Citation Score: 267.636208
- Max Citation Score: 307.86633
- Similarity Product: 216.2694863261712

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test